Copeland Capital Management LLC Has $13.27 Million Holdings in Cencora, Inc. $COR

Copeland Capital Management LLC trimmed its holdings in Cencora, Inc. (NYSE:COR) by 16.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,245 shares of the company’s stock after selling 8,243 shares during the quarter. Copeland Capital Management LLC’s holdings in Cencora were worth $13,271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Kemnay Advisory Services Inc. acquired a new position in Cencora during the 4th quarter valued at $25,000. Oakworth Capital Inc. acquired a new stake in Cencora in the 4th quarter worth $26,000. Elyxium Wealth LLC bought a new position in shares of Cencora during the 4th quarter worth about $27,000. Archer Investment Corp increased its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC acquired a new position in shares of Cencora during the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

NYSE:COR opened at $307.72 on Friday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The company has a 50-day moving average of $279.98 and a 200-day moving average of $317.68. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a market capitalization of $59.87 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 1.71 and a beta of 0.58.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its Board of Directors has authorized a share buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to purchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the transaction, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on COR. Robert W. Baird reduced their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Citigroup reduced their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Barclays decreased their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.